Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 9, 2012, Pages

  Chong, Jimmy ^a   Karner, Charlotta ^b   Poole, Phillippa ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b BMJ   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FORMOTEROL; INDACATEROL; SALMETEROL; TIOTROPIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SALBUTAMOL; SCOPOLAMINE DERIVATIVE;

ADVERSE EVENT; ALL CAUSE MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DISEASE SPECIFIC MORTALITY; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE ASSESSMENT; REVIEW; SMOKING; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TRANSITIONAL DYSPNOEA INDEX; TREATMENT DURATION; TREATMENT WITHDRAWAL; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; ETHANOLAMINES; HOSPITALIZATION; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES;

EID: 84872336831     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009157.pub2     Document Type: Review

References (128)

1. Briggs Jr D, Covelli H, Lapidus R, Bhattacharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared to salmeterol in COPD patients [Abstract]. American Thoracic Society 100th International Conference, May 21-26, 2004, Orlando. 2004:C22 Poster 511.
2. Briggs Jr DD, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulmonary Pharmacology & Therapeutics 2005;18(6):397-404.
3. Brusasco V, Menjoge SS, Kesten S. Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society. 2006:A110 [Poster J10].
4. Langley J, Briggs Jr D, Bhattacharya S, Kesten S, Cassino C. Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long acting beta-agonist use [Abstract]. European Respiratory Journal 2004;24(Suppl 48):289s.
5. Bateman ED, Hodder R, Miravitlles M, Lee A, Towse L, Serby C. A comparative trial of tiotropium, salmeterol and placebo: health-related quality of life. European Respiratory Journal 2001;18(Suppl 33):26s.
6. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58(5):399-404.
7. Brusasco V, Menjoge SS, Kesten S. Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [abstract]. American Thoracic Society 99th International Conference. 2003:B024 Poster 420.
8. Brusasco V, Menjoge SS, Kesten S. Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society. 2006:A110 [Poster J10].
9. Brusasco V, Thompson P, Vincken W, Lee A, Towse L, Witek TJ. Improvement of dyspnea following of six months treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal 2001;18(Suppl 33):26s.
10. Donohue JF. Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine 2002;165(Suppl 8):A227.
11. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine 2003;97(9):1014-20.
12. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, et al.A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122(1):47-55.
13. Donohue JF, van Noord JA, Langley SJ, Lee A, Kesten S, Towse LJ. Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal 2001;18(Suppl 33):26s.
14. Gunther K, Lee A, Kesten S, Towse L. Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress: Amsterdam, June 2002. 2002:112.
15. Hodder R, Kesten S, Menjoge S, Viel K. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. International Journal of COPD 2007;2(2):157-67.
16. Langley J, Briggs Jr D, Bhattacharya S, Kesten S, Cassino C. Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long acting beta-agonist use [Abstract]. European Respiratory Journal 2004;24(Suppl 48):289s.
17. Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, Monz BU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care 2007;8(2):123-35.
18. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, et al.Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. European Respiratory Journal 2011;38:797-803.
19. Dunn LJ, Buhl R, Lassen C, Henley M, Kramer B. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD [Abstract]. Chest. 2010; Vol. 138:719A.
20. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, et al.Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory & Critical Care Medicine 2010;182(2):155-62.
21. Fogarty C, Hebert J, Iqbal A, Owen R, Higgins M, Kramer B. Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 12-16. 2009:[P2025].
22. Jones PW, Mahler DA, Gale R, Owen R, Kramer B. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine 2011;105(6):892-9.
23. Lotvall J, Cosio BG, Iqbal A, Swales J, Owen R, Kramer B, et al.Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 12-16. 2009:[P2029].
24. Mahler D, Palange P, Iqbal A, Owen R, Higgins M, Kramer B. Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 12-16. 2009:[E4360].
25. Worth H, Kleerup E, Iqbal A, Owen R, Kramer B, Higgins M. Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 12-16. 2009:[P2030].
26. Yorgancioglu A, Mahler D, Iqbal A, Owen R, Higgins M, Kramer B. Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 12-16. 2009:[P2028].
27. Gani R, Griffin J, Kelly S, Rutten-van Molken M. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group 2010;19(1):68-74.
28. Mahmud AM, Gupta DK, Khan AS, Hassan R, Hossain A, Rahman M, et al.Comparison of once daily tiotropium with twice daily salmeterol in Bangladeshi patients with moderate COPD [Abstract]. Respirology 2007;12(Suppl 4):A211.
29. Maniadakis N, Tzanakis N, Fragoulakis V, Hatzikou M, Siafakas N. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Current Medical Research and Opinion 2006;22(8):1599-607.
30. Naik S, Kamal KM, Keys PA, Mattei TJ. Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease. ClinicoEconomics and Outcomes Research: CEOR 2010;2:25-36.
31. Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clinic Proceedings 2007;82(5):575-82.
32. Oostenbrink JB, Rutten-van Molken MP, Monz BU, FitzGerald JM. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 2005;8(1):32-46.
33. Rutten-van Molken MP, Oostenbrink JB, Miravitlles M, Monz BU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care 2007;8(2):123-35.
34. Arievich H, Potena A, Fonay K, Vogelmeier CF, Overend T, Smith J, et al.Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal 2006;28(Suppl 50):440s [P2514].
35. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respiratory Medicine 2008;102(11):1511-20.
36. Vogelmeier CF, Harari SA, Fonay K, Beier J, Overend T, Till D, et al.Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal 2006;28(Suppl 50):429s [P2506].
37. Beeh KM, Hederer B, Glaab T, Muller A, Rutten-van Moelken M, Kesten S, et al.Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. International Journal of COPD 2009;4(1):119-25.
38. Beeh KM, Vogelmeier C, Rutten-van Mölken M, Rabe KF, Glaab T, et al.Tiotropium vs salmeterol in GOLD II and maintenance-naive COPD patients: subgroup analyses of POET-COPD™ trial [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24-28 2011; Vol. 38, issue 55:20s [P251].
39. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MPMH, Beeh KM, et al.Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New England Journal of Medicine 2011;364(12):1093-103.
40. Vogelmeier C, Rabe K, Beeh KM, Glaab T, Schmidt H, Rutten-van Mölken M, et al.Tiotropium reduces exacerbations versus salmeterol irrespective of baseline ICS treatment in the Poet-COPD; Study [Abstract]. American Journal of Respiratory and Critical Care Medicine. 2011; Vol. 183:A1600.
41. Vogelmeier CF, Beeh KM, Rutten-van Molken M, Glaab T, Schmidt H, Hederer B. Baseline characteristics according to gender in a large exacerbations trial [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A4495.
42. Barnes P, Pocock S, Magnussen H, Iqbal A, Lawrence D, Kramer B, et al.Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. American Journal of Respiratory and Critical Care Medicine. 2009; Vol. 179, issue Meeting Abstracts:A4543.
43. Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, et al.Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics 2010;23(3):165-71.
44. Fogarty C, Worth H, Hebert J, Iqbal A, Owen R, Higgins M, et al.Sustained 24-h bronchodilation with indacaterol once-daily in COPD: a 26-week efficacy and safety study. American Journal of Respiratory and Critical Care Medicine. 2009; Vol. 179, issue 1 Meeting Abstracts:A4547.
45. Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, et al.A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine 2008;102(7):1033-44.
46. Rennard SI, Chapman KR, Luthra A, Swales J, Lassen C, Owen R, et al.Once-daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD). Chest 2009;136(4):4S-f.
47. Chapman KR, Fogarty CM, Peckitt C, Lassen C, Kramer B. Patient handling and preference for the single-dose dry-powder inhalers used with indacaterol and tiotropium [Abstract]. Chest. 2010; Vol. 138:470A.
48. Di Marco F, Carlucci P, Ccarlucci P, Verga M, Mondoni M, Pistone A, et al.A single dose of formoterol (FOR) and tiotropium (TIO) reduce hyperinflation in COPD patients [Abstract]. European Respiratory Journal 2003;22(Suppl 45):Abstract No: [P1844].
49. Di Marco F, Verga M, Santus P, Cazzola M, Mondoni M, Belloi E, et al.Formoterol (Modulite ®), tiotropium and their combination in patients with acute exacerbations of chronic bronchitis: preliminary data [Abstract]. European Respiratory Journal 2005;26(Suppl 49):Abstract No. 1905.
50. Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respiratory Medicine 2006;100(11):1925-32.
51. Donohue J, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. Dose-related efficacy of GSK573719: a long-acting muscarinic receptor antagonist (LAMA) with sustained 24-hour activity in COPD [Abstract]. Chest 2011; Vol. 140, issue 4:1043A.
52. Golubev L, Gorbunova M, Babak S, Tatarskiy. Sleep architecture in COPD patients during salmeterol versus tiotropium bromide treatment [Abstract]. European Respiratory Journal 2006;28(Suppl 50):199s [P1197].
53. Gross NJ, Paulson D, Kennedy D, Korducki L, Kesten S. A comparison of maintenance tiotropium and salmeterol on arterial blood gas tensions in patients with COPD [Abstract]. Respiratory Care 2003;48(11):1081.
54. Meyer T, Brand P, Reitmeir P, Scheuch G. Effect of formoterol, salbutamol and tiotropium bromide on the efficacy of lung clearance in patients with COPD [Abstract]. American Thoracic Society International Conference, May 16-21, 2008, Toronto. 2008:A646[#F1].
55. Meyer T, Reitmeir P, Brand P, Herpich C, Sommerer K, Schulze A, et al.Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD. Respiratory Medicine 2011; Vol. 105, issue 6:900-6.
56. Reisner C, Fogarty C, Spangenthal S, Dunn L, Kerwin EM, Quinn D, et al.Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine 2011; Vol. 183, issue Meeting Abstracts:A6435.
57. Reisner C, St. Rose E, Strom S, Fischer T, Golden M, Thomas M, et al.Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24-28 2011; Vol. 38, issue 55:150s [P879].
58. Rossi A, Centanni S, Cerveri I, Gulotta C, Foresi A, Cazzola M, et al.Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respiratory Medicine 2012; Vol. 106, issue 1:84-90.
59. Tashkin D, Donohue J, Mahler D, Huang H, Schaefer K, Hanrahan J, et al.Effect of arformoterol twice daily, tiotropium once daily, and their combination in subjects with COPD [Abstract]. Chest 2008;134(4):104003s.
60. Tashkin DP, Donohue JF, Mahler DA, Huang H, Goodwin E, Schaefer K, et al.Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respiratory Medicine 2009;103(4):516-24.
61. ten Hacken NH, van der Haart H, Grevink R, Thompson S, Roemer W, Postma DS. Bronchodilation improves endurance but not muscular efficiency in COPD [Abstract]. American Thoracic Society International Conference, May 18-23, 2007, San Francisco, California, USA. 2007:Poster #M72.
62. van der Vaart H, Postma DS, Grevink R, Roemer W, ten Hacken N. Bronchodilation improves endurance but not muscular efficiency in chronic obstructive pulmonary disease. International Journal of COPD 2011;6:229-35.
63. van Noord JA, Aumann J, Janssens E, Folgering H, Mueller A, Cornelissen JPG. Tiotropium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatment periods [abstract]. American Thoracic Society 99th International Conference. 2003:A035 Poster D82.
64. van Noord JA, Aumann J, Janssens E, Mueller A, Cornelissen PJ. Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract]. American Thoracic Society 99th International Conference. 2003:B024 Poster 421.
65. van Noord JA, Aumann J, Janssens E, Mueller A, Cornelissen PJG. A comparison of the 24 hour bronchodilator effect of tiotropium QD [T10] salmeterol BID [SALM] or their combination in COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:[B93] [Poster: 311].
66. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, et al.Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. European Respiratory Journal 2005;26(2):214-22.
67. Van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, et al.Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129(3):509-17.
68. van Noord JA, Smeets JJ, Otte A, Bindels H, Mueller A, Cornellissen PJG. The effect of tiotropium, salmeterol and it's combination on dynamic hyperinflation in COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:[B93] [Poster: 310].
69. Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M, et al.Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respiratory Research. 2010; Vol. 11:135.
70. Garcia Ruiz AJ, Leiva Fernandez F, Martos Crespo F. Cost-effectivenessanalysis of tiotropium compared to ipratropium and salmeterol. Archivos de Bronconeumología 2005;41:242-8.
71. Geitona M, Hatzikou M, Bania E. Economic evaluation of indacaterol versus tiotropium or formoterol for patients with moderate to severe COPD in Greece. Value in Health. 2011; Vol. ISPOR 14th Annual European Congress, Madrid, Spain.
72. Price D, Gray A, Gale R, Asukai Y, Mungapen L, Lloyd A, et al.Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respiratory Medicine 2011;105(11):1635-47.
73. Sanz-Martinez H, Perez-Maroto MT. Cost-efficacy analysis of tiotropium versus ipratropium and salmeterol in the treatment of chronic obstructive pulmonary disease. Farmacia Aten Primaria 2004;2:72-82.
74. Schramm W, Haake D, Brandt A. Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease. Praxis 2005;94(46):1803-10.
75. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MMK, et al.Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 3.
76. Barr RG, Bourbeau J, Camargo Carlos A. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 2.
77. Beeh KM, Beier J. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Advances in Therapy 2010;27(3):150-9.
78. Beier J, Beeh KM. Long-acting beta-adrenoceptor agonists in the management of COPD: focus on indacaterol. International Journal of Chronic Obstructive Pulmonary Disease. 2011/08/05 2011; Vol. 6:237-43. [1178-2005: (Electronic)].
79. Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respiratory Medicine 2008;102(2):173-88.
80. Boehringer Ingelheim. Tiotropium (SPIRIVA®) RESPIMAT®: Evaluation of fatal events. www.trials.boehringer-ingelheim.com/res/trial/data/pdf/Pooled_Analysis_U10-3255-01.pdf 2010.
81. Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundback B, Donaldson GC, et al.A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value in Health 2004;7(2):153-67.
82. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine 2007;356(8):775-89.
83. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL, et al.A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal 2002;19(2):217-24.
84. Chapman KR, Arvidsson P, Chuchalin AG, Dhillon DP, Faurschou P, Goldstein RS, et al.The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. Canadian Respiratory Journal 2002;9(3):178-85.
85. Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 1.
86. National Institutes of Health. Comparison of indacaterol and tiotropium on lung function and related outcomes in patients with chronic obstructive pulmonary disease (COPD) (INVIGORATE). http://clinicaltrials.gov/ct2/show/NCT00845728?term=tiotropium+indacaterol+copd&rank=6 2012.
87. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al.Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65(6):473.
88. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, et al.A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122(1):47-55.
89. Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 2011; Vol. 6:477.
90. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313(7052):275-83.
91. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. European Respiratory Journal 2006; Vol. 27, issue 3:547-55. [CTG: NCT00274014].
92. Effing T, Monninkhof Evelyn EM, van der Valk Paul PDLPM, Zielhuis Gerhard GA, Walters EH, van der Palen Job J, et al.Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4.
93. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. http://www.goldcopd.com 2009.
94. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008], The Cochrane Collaboration. Available from www.cochrane-handbook.org 2008.
95. Hutchinson A, Brand C, Irving L, Roberts C, Thompson P, Campbell D. Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. Internal Medicine Journal 2010;40(5):364-71.
96. Johnson M. The beta-adrenoceptor. American Journal of Respiratory and Critical Care Medicine 1998;158(5 Pt 3):S146-53.
97. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. American Journal of Respiratory and Critical Care Medicine 1997;155(4):1283-9.
98. Jones P. St. Georges Respiratory Questionnaire: MCID. COPD 2005;2:75-9.
99. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 8.
100. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 3.
101. Karner C, Cates CJ. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 9.
102. Karner C, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 4.
103. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al.Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. European Respiratory Journal 2011;37(2):273-9.
104. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 4.
105. Miravitlles M, Murio C, Guerrero T, Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121(5):1449-55.
106. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003;123(3):784-91.
107. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease (updated). http://www.nice.org.uk/guidance/CG101 2012.
108. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper Jr JAD, Korducki L, et al.Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Annals of Internal Medicine 2005; Vol. 143, issue 5:317-26. [CTG: NCT00274547].
109. Oostenbrink JB, Rutten-van Molken MP. Resource use and risk factors in high-cost exacerbations of COPD. Respiratory Medicine 2004;98(9):883-91.
110. Oostenbrink JB, Rutten-van Molken MP, Al MJ, Van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. European Respiratory Journal 2004;23(2):241-9.
111. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al.Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment. 2004/09/14 2004; Vol. 8, issue 36:iii-iv, ix-xi, 1-158.
112. Proskocil BJ, Fryer AD. Beta2-agonist and anticholinergic drugs in the treatment of lung disease. Proceedings of the American Thoracic Society 2005;2(4):305-10; discussion 311-2.
113. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, et al.Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2001;163(5):1087-92.
114. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
115. Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting β-agonists in stable COPD. Chest 2008;133(5):1079-87.
116. Sears MR. Long-acting bronchodilators in COPD. Chest 2008;133(5):1057-8.
117. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. American Journal of Medicine 2004;116(5):325-31.
118. Spencer S, Karner C, Cates CJ, Evans DJ. Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 12.
119. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006;61(2):122-8.
120. Tanaka Y, Horinouchi T, Koike K. New insights into beta-adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation. Clinical and Experimental Pharmacology and Physiology 2005;32(7):503-14.
121. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al.A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal Medicine 2008;359(15):1543-54.
122. van der Meer RM, Wagena E, Ostelo RWJG, Jacobs AJE, van Schayck OP. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2001, Issue 1.
123. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, et al.Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. European Respiratory Journal 2002;19(2):209-16.
124. Wallukat G. The beta-adrenergic receptors. Herz 2002;27(7):683-90.
125. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 5.
126. World Health Organization. Chronic Respiratory Diseases. http://www.who.int.
127. Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respiratory Medicine 2000;94(3):204-13.
128. Yohannes AM, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respiratory Care 2011;56(4):477-87.